EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Early Bird Rate Ending for What’s Hot in Cancer Immunotherapy 2017 on 6/14

Xconomy Seattle — 

Three years ago, Xconomy gathered some of the field’s experts to talk about the promises of harnessing the immune system to fight cancer. Now, it’s time to gather again in Seattle to look back at the last three years and look ahead to the future. Join us on June 14 at the Fred Hutchinson Cancer Research Center to discuss this and more.

We’re still developing the day’s program, but speakers from our last Seattle cancer immunotherapy event included:

  • Hans Bishop, CEO, Juno Therapeutics
  • Mitch Gold, Executive Chairman, Alpine BioSciences
  • Rob Hershberg, CEO, VentiRx Pharmaceuticals (now CSO at Celgene)
  • Deborah Law, VP, Biologics Discovery, Merck (now CSO at Jounce Therapeutics)
  • Ira Mellman, VP, Cancer Immunology, Genentech
  • Robert Nelsen, Managing Director, Arch Venture Partners
  • Stan Riddell, Researcher, Fred Hutchinson Cancer Research Center
  • Chad Robins, CEO, Adaptive Biotechnologies

Today, March 22, is the last day you can save $100 with our Early Bird rate. Don’t miss this great opportunity to save and buy your ticket today!